Jefferies Group set a $13.00 price objective on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in a research note issued to investors on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Xenon Pharmaceuticals from a hold rating to a buy rating and set a $8.75 price target on the stock in a report on Wednesday, November 9th. Stifel Nicolaus assumed coverage on Xenon Pharmaceuticals in a report on Friday, October 21st. They set a buy rating and a $18.00 price target on the stock. Guggenheim assumed coverage on Xenon Pharmaceuticals in a report on Monday, September 26th. They set a buy rating and a $20.00 price target on the stock. Finally, Canaccord Genuity restated a buy rating and set a $16.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 5th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average target price of $15.15.

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) traded up 1.29% during trading on Monday, reaching $7.85. 15,646 shares of the company were exchanged. The company’s market capitalization is $140.46 million. The firm’s 50 day moving average price is $8.08 and its 200 day moving average price is $7.56. Xenon Pharmaceuticals has a one year low of $5.65 and a one year high of $9.32.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.08. Xenon Pharmaceuticals had a negative return on equity of 34.72% and a negative net margin of 449.72%. Equities research analysts forecast that Xenon Pharmaceuticals will post ($1.57) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Xenon Pharmaceuticals Inc. (XENE) Given a $13.00 Price Target at Jefferies Group” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/xenon-pharmaceuticals-inc-xene-given-a-13-00-price-target-at-jefferies-group.html.

A number of institutional investors have recently modified their holdings of XENE. Opaleye Management Inc. boosted its position in shares of Xenon Pharmaceuticals by 2.5% in the second quarter. Opaleye Management Inc. now owns 410,000 shares of the biopharmaceutical company’s stock valued at $2,419,000 after buying an additional 10,000 shares during the period. M&T Bank Corp bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at $115,000. K2 Principal Fund L.P. bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at $122,000. Monashee Investment Management LLC bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at $203,000. Finally, Perceptive Advisors LLC boosted its position in shares of Xenon Pharmaceuticals by 110.3% in the second quarter. Perceptive Advisors LLC now owns 432,800 shares of the biopharmaceutical company’s stock valued at $2,553,000 after buying an additional 227,000 shares during the period. Institutional investors and hedge funds own 55.44% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).

5 Day Chart for NASDAQ:XENE

Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.